Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis

被引:59
作者
Kollum, M
Farb, A
Schreiber, R
Terfera, K
Arab, A
Geist, A
Haberstroh, J
Wnendt, S
Virmani, R
Hehrlein, C
机构
[1] Univ Freiburg, Dept Cardiol & Angiol, D-79106 Freiburg, Germany
[2] Armed Forces Inst Pathol, Washington, DC 20306 USA
[3] Univ Freiburg, Dept Expt Surg, D-79106 Freiburg, Germany
[4] JOMED, Rangendingen, Germany
关键词
drug-eluting stent; inflammation; tacrolimus; restenosis;
D O I
10.1002/ccd.20213
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymer stent coatings may not be suitable for drug elution because of inherent proinflammatory effects. A previous study suggested a beneficial effect of a stent eluting tacrolimus from a nanoporous ceramic aluminum oxide coating in a rabbit restenosis model. We investigated whether this stent is effective in preventing in-stent restenosis in a porcine restenosis model. Thirty-four juvenile swine underwent balloon overstretch injury and were subjected to implantation of either stainless steel (bare) stents, bare stents coated with nanoporous aluminum oxide alone, and coated stents eluting 50 and 180 mug of tacrolimus (FK506). In-stent restenosis was quantified at 1 and 3 months after stent placement by histomorphometry. A significant increase of neointimal hyperplasia was noted with the stents coated with aluminum oxide alone compared with bare stents (2.92 +/- 1.02 and 1.38 +/- 0.51 mm(2), respectively; P<0.02). In all arteries containing coated stents, particle debris was found in the media and neointima, resulting in augmented vascular inflammation. In the group of stents coated with aluminum oxide, FK506 elution at a dose 180 jig reduced neointimal hyperplasia vs. no drug elution (1.66 +/- 0.49 vs. 2.92 +/- 1.02 mm(2); 180 mug vs. ceramic alone; P<0.03). At a dose of 50 mug stent-based delivery of FK506, no reduction of neointimal hyperplasia was found (2.88 +/- 1.31 and 2.92 +/- 1.02 mm(2), respectively; P = NS; FK506 vs. ceramic alone). In summary, particle debris shed from a drug-eluting aluminum oxide coating of a stainless steel stent counteracts potential antiproliferative effects of stent-based tacrolimus delivery in a porcine model of restenosis. We propose that stent coatings eluting drugs need to be routinely tested for being tightly anchored into the stent surface. Alternatively, omission of any coating used as a drug reservoir may eliminate inflammatory particle debris after placement of drug-eluting stents. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:85 / 90
页数:6
相关论文
共 27 条
  • [1] Changrong L, 2000, NUCL INSTR MED PHYS, V169, P21
  • [2] Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation - Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up
    Degertekin, M
    Serruys, PW
    Foley, DP
    Tanabe, K
    Regar, E
    Vos, J
    Smits, PC
    van der Giessen, WJ
    van den Brand, M
    de Feyter, P
    Popma, JJ
    [J]. CIRCULATION, 2002, 106 (13) : 1610 - 1613
  • [3] Drachman Douglas E, 2002, Rev Cardiovasc Med, V3 Suppl 5, pS31
  • [4] Pathological analysis of local delivery of paclitaxel via a polymer-coated stent
    Farb, A
    Heller, PF
    Shroff, S
    Cheng, L
    Kolodgie, FD
    Carter, AJ
    Scott, DS
    Froehlich, J
    Virmani, R
    [J]. CIRCULATION, 2001, 104 (04) : 473 - 479
  • [5] Oral everolimus inhibits in-stent neointimal growth
    Farb, A
    John, M
    Acampado, E
    Kolodgie, FD
    Prescott, MF
    Virmani, R
    [J]. CIRCULATION, 2002, 106 (18) : 2379 - 2384
  • [6] Grube E, 2002, Minerva Cardioangiol, V50, P469
  • [7] Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions
    Grube, E
    Silber, S
    Hauptmann, KE
    Mueller, R
    Buellesfeld, L
    Gerckens, U
    Russell, ME
    [J]. CIRCULATION, 2003, 107 (01) : 38 - 42
  • [8] HEHRLEIN C, 1995, CORONARY ARTERY DIS, V6, P581
  • [9] Failure of a novel balloon-expandable γ-emitting (103Pd) stent to prevent edge effects
    Hehrlein, C
    DeVries, JJ
    Arab, A
    Haller, SD
    Schloesser, K
    Tio, FO
    Fischell, TA
    [J]. CIRCULATION, 2001, 104 (19) : 2358 - 2362
  • [10] Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries - A serial volumetric intravascular ultrasound analysis from the ASian paclitaxel-eluting stent clinical trial (ASPECT)
    Hong, MK
    Mintz, GS
    Lee, CW
    Song, JM
    Han, KH
    Kang, DH
    Song, JK
    Kim, JJ
    Weissman, NJ
    Fearnot, NE
    Park, SW
    Park, SJ
    [J]. CIRCULATION, 2003, 107 (04) : 517 - 520